Home

MARKSMAN HEALTHCARE COMMUNICATIONS | A DATA SCIENCE COMPANY

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications is a HEOR, scientific outsourcing and research consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, RWE and market access support to large and small life science companies. We also provide services pertaining to
“Scientific Writing, Medical Information, and Healthcare Analytics”

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

HEOR

Medical Affairs

Data Curation

Patient Registry

Data Analytics

LATEST FROM BLOG

04Oct 2018

India is in the middle of health transformation. Although infectious diseases like tuberculosis, malaria, dengue, H1N1 pandemic influenza and antimicrobial resistance continue to pose health and economic burden, the country is also facing challenges with chronic non-communicable diseases, such as cardiovascular diseases, diabetes, cancer; which are the leading cause of mortality. Social and economic determinants […]

22Sep 2018

The discipline of ‘health economics’ has significantly progressed to become more inclusive, beginning with only cost-benefit analyses of public health programs, such as vaccinations, to evolving into a large area of health technology assessments (HTA). Cost-effectiveness analyses are a routine practice in HTA and are performed virtually for every new health technology. Healthcare industry as […]

13Aug 2018

Network meta-analysis (NMA) is a type of meta-analysis that adds an additional variable to a meta-analysis, and instead of a simple summation of trials that have evaluated the same treatment, several different treatments are compared by statistical inference.1 NMA is also referred to as mixed treatments comparison or multiple treatments comparison meta-analysis.2,3,4 It was recognised […]

LATEST PRESENTATIONS

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Everolimus as a Combination Therapy in the Treatment of Metastatic Breast Cancer: A Systemic Review and Meta-analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Vedolizumab in the Treatment of Ulcerative Colitis: A Systemic Review and Meta-analysis

  • DIA 2018 Global Annual Meeting 2018, June 24-28, 2018, Boston, USA

    Role of Social Media in Patient Reported Outcomes (PRO) Research

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Enzalutamide in Metastatic Prostate Cancer Patients: A Systematic Review and Meta-Analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Adaptive Licensing and Real World Evidence (RWE)

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    A Comparison of AMSTAR and ROBIS tools for Methodological Quality Assessment of Systematic reviews of Alzheimer’s Disease

WHAT OUR CLIENT SAY

OUR COLLABORATIONS